Patents Examined by Howard E. Schain
  • Novel peptides having plateler aggregation inhibitory activity
    Patent number: 5100875
    Abstract: The subject of the invention is peptide derivatives corresponding to formulaX.sup.1 - X.sup.2 - Gly - Asp-X.sup.3 - X.sup.4 (I)in which:X.sup.1 represents a hydrogen atom, a N-protecting group, an amino acid residue or a N-protected amino acid residue,X.sup.2 represents a residue of L-Arg or D-Arg, L-Orn or D-Orn, N-aminocarbonyl -L-Orn or N-aminocarbonyl-D-Orn, or L-Lys, or D-Lys,X.sup.3 represents a residue of L-Trp, D-Trp, L-Leu, D-Leu, L-Ile, D-Ile, L-Phe, D-Phe or a chain of 2 or 3 of these residues, andX.sup.4 represents a -OH group, -NH.sub.2 group, -OR.sup.1 group in which R.sup.1 represents an alkyl radical of C.sub.1 to C.sub.4, a NHR.sup.2 group in which R.sup.2 represents an alkyl radical of C.sub.1 to C.sub.4, or an amino acid residue.These derivatives are useful in therapy on account of their platelet aggregation inhibiting activity.
    Type: Grant
    Filed: October 22, 1990
    Date of Patent: March 31, 1992
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Laboratoire L. Lafon
    Inventor: Gerard A. Marguerie de Rotrou
  • Use of a Bacillus thuringiensis microbe for controlling lesser meal-worm, Alphitobius diaperinus
    Patent number: 5100665
    Abstract: The subject invention concerns the use of a novel and useful bioinsecticide against the lesser mealworm (Alphitobius diaperinus). The lesser mealworm is a devastating pest in the poultry industry. The bioinsecticide of the subject invention is a novel B. thuringiensis microbe referred to as B.t. PS86B1, or mutants thereof. The spores or toxin crystals of this microbe are useful to control the lesser mealworm in various environments.
    Type: Grant
    Filed: September 11, 1990
    Date of Patent: March 31, 1992
    Assignee: Mycogen Corporation
    Inventors: Leslie A. Hickle, Gregory A. Bradfisch, Jewel M. Payne
  • Protein composition inducing a binding between parts of mineralized tissue
    Patent number: 5098891
    Abstract: A composition for use in inducing binding between parts of mineralized tissue by regeneration of mineralized tissue on at least one of the parts, containing as an active constituent a protein fraction originating from a precursor to dental enamel, so called enamel matrix;a process for inducing binding between parts of living mineralized tissue by regeneration of mineralized tissue on at least one of the parts using such composition.
    Type: Grant
    Filed: April 22, 1991
    Date of Patent: March 24, 1992
    Assignee: Bioventures N.V.
    Inventors: Lars Hammarstrom, Leif Blomlof, Sven Lindskog
  • Use of a bacillus thuringiensis microbe for controlling lesser mealworm, alphitobius diaperinus
    Patent number: 5098705
    Abstract: The subject invention concerns the use of a novel and useful bioinsecticide against the lesser mealworm (Alphitobius diaperinus). The lesser mealworm is a devastating pest in the poultry industry. The bioinsecticide of the subject invention is a novel B. thuringiensis microbe referred to as B.t. PS40D1, or mutants thereof. The spores or toxin crystals of this microbe are useful to control the lesser mealworm in various environments.
    Type: Grant
    Filed: September 11, 1990
    Date of Patent: March 24, 1992
    Assignee: Mycogen Corporation
    Inventors: Leslie A. Hickle, Gregory A. Bradfisch, Jewel M. Payne
  • Interferon-alpha 76
    Patent number: 5098703
    Abstract: A new polypeptide, called IFN-.alpha.76, produced by E. coli transformed with a newly isolated and characterized human IFN-.alpha. gene is described. The polypeptide exhibits interferon activities such as antiviral activity, cell growth regulation, and regulation of production of cell-produced substances.
    Type: Grant
    Filed: September 2, 1982
    Date of Patent: March 24, 1992
    Assignee: Cetus Corporation
    Inventor: Michael A. Innis
  • Pharmaceutical containing tissue protein PP4, a process for the preparation of PP4 and for the pasteurization thereof, and the use of PP4
    Patent number: 5097019
    Abstract: An agent for the therapy or prophylaxis of disturbances of hemostasis, which contains tissue protein PP4, a process for the purification of PP4 by means of a hydrophobic adsorbent which is insoluble in water, and a process for the pasteurization of a solution containing PP4 in the presence of calcium ions and of at least one mono- or oligosaccharide or sugar alcohol and, where appropriate, of an amino acid, and the use of PP4, are described.
    Type: Grant
    Filed: February 1, 1991
    Date of Patent: March 17, 1992
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Hartmut Lobermann, Christiane Bornmann
  • Fluorine containing atrial natriuretic peptides
    Patent number: 5095004
    Abstract: Disclosed herein are derivatives of atrial natriuretic peptides which are characterized by having (at position 124 or at positions 106 and 124) a phenylalanyl residue bearing a fluoro or trifluoromethyl substituent on the aromatic portion thereof. Optionally, the exocyclic N-terminal peptide segment and the first cystienyl residue (at position 105) are replaced by an optionally substituted thioalkanoyl residue. The derivatives possess useful diuretic, natriuretic and antihypertensive activities.
    Type: Grant
    Filed: March 14, 1988
    Date of Patent: March 10, 1992
    Assignee: Bio-Mega Inc.
    Inventors: Sumanas Rakhit, Mahesh H. Goghari
  • Compositions and method for the treatment or prophylaxis of sepsis or septic shock
    Patent number: 5093117
    Abstract: Pharmaceutical compositions useful for the treatment or prophylaxis of Gram-negative bacteremia or septic shock contain a bactericidal effective amount of polyclonal immunoglobulins against Gram-negative bacteria and a blood clot-dissolving effective amount of protein C. The compositions may further contain one or more protein C cofactors and monoclonal antibodies against Gram-negative bacterial endotoxins.A method for the treatment or prophylaxis of Gram-negative bacteremia or septic shock comprises administering, either together or separately, a bactericidal effective amount of polyclonal immunoglobulins against Gram-negative bacteria and a blood clot-dissolving effective amount of protein C. The method may optionally include administering one or more protein C cofactors and monoclonal antibodies against Gram-negative bacterial endotoxins.
    Type: Grant
    Filed: January 24, 1989
    Date of Patent: March 3, 1992
    Assignee: Baxter International Inc.
    Inventors: Joyce E. Lawrence, Michael J. Griffith, Melaine Alpern
  • Process for the production of gelatin from fish skins
    Patent number: 5093474
    Abstract: A process for the production of gelatin from fish skins comprises the steps of: (a) cleaning the skins in order to remove therefrom substantially all superfluous material; (b) treating with dilute aqueous alkali; (c) washing with water until the washing water is substantially neutral; (d) treating with dilute aqueous mineral acid; (e) washing with water until the washing water is substantially neutral; (f) treating with dilute aqueous citric acid and/or another suitable organic acid; (g) washing with water until the washing water is substantially neutral; and (h) extracting with water at elevated temperatures not above about 55.degree. c., the washed citric acid-treated skins. In practice, the present process employs much lower temperatures than known heretofore for the treatment steps, which results in a high quality product (e.g. absence of a fishy smell), compared with the prior art.
    Type: Grant
    Filed: April 12, 1989
    Date of Patent: March 3, 1992
    Assignee: Bar Ilan University
    Inventors: Shlomo Grossman, Margalit Bergman
  • Treatment of inflammation
    Patent number: 5093316
    Abstract: A method for treating pulmonary inflammation and alpha-1-antitrypsin deficiencies by the administration of an effective amount of microcrystalline alpha-1-antitrypsin, its salt or derivative by inhalation, alone or with other serine protease inhibitors, and the pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 2, 1990
    Date of Patent: March 3, 1992
    Inventors: John Lezdey, Allan Wachter
  • Biologically active compounds from blue-green algae
    Patent number: 5091368
    Abstract: Novel bioactive compounds have been isolated from blue-green alga. These compounds have been found to have antitumor, antiviral, and immunomodulatory properties. Thus, these compounds, and derivatives thereof, can be used to treat human and animal tumors, inhibit viral growth, and provide immunomodulatory activity.
    Type: Grant
    Filed: August 8, 1990
    Date of Patent: February 25, 1992
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Frank Koehn, Sue S. Cross, Ross E. Longley
  • Peptides having ANF activity
    Patent number: 5091366
    Abstract: Analogs of the 17-membered ring portion of ANF wherein the cysteine moiety is replaced with dipeptidyl moieties, specifically, Phe-Pro, NMP-Pro, Pro-Pro, Val-Pro, Lys-Pro, Ile-Pro, Arg-Pro, HAr-Pro, Dly-Pro, Arg-Pro, Lys-BAr, Arg-Pro, CyA-CyA, Cys-Cys, or with .alpha.-aminoheptanoic acid result in analogs of ANF having increased potencies and metabolic stability.
    Type: Grant
    Filed: June 4, 1990
    Date of Patent: February 25, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Ruth F. Nutt, Terrence M. Ciccarone, Stephen F. Brady, Daniel F. Veber
  • Preparation of a polymer/interleukin-2 conjugate
    Patent number: 5089261
    Abstract: The present invention is a process for preparing a pharmaceutical composition comprising a biologically active conjugated protein. It comprises a polyethylene glycol or a polyoxyethylated polyol conjugated to IL-2. This protein is conjugated to reduce its immunogenicity, and increase its solubility, and increase its circulating in vivo half-life.
    Type: Grant
    Filed: September 29, 1989
    Date of Patent: February 18, 1992
    Assignee: Cetus Corporation
    Inventors: Danute E. Nitecki, Nandini Katre, Robert J. Goodson, Lois Aldwin
  • Enhancing growth of megakaryocytes in mammals using interleuking 6
    Patent number: 5087448
    Abstract: A therapeutic method for treating mammals by administering an effective dosage of a substance comprising interleukin 6 or interleukin 6 and interleukin 3 into the mammal for enhancing the growth of megakaryocytes and platelets.
    Type: Grant
    Filed: February 2, 1989
    Date of Patent: February 11, 1992
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Samuel A. Burstein
  • Fluorinated gelatin and process for its preparation
    Patent number: 5087694
    Abstract: The present invention relates to modified gelatin containing polyfluorinated substituents grafted on to the protein chain.It further relates to the process for the preparation of this modified gelatin, which consists in reacting a polyfluorinated derivative containing a group capable of reacting with the OH or NH.sub.2 groups of the gelatin in aqueous solution.Application: photographic film preparations.
    Type: Grant
    Filed: December 15, 1989
    Date of Patent: February 11, 1992
    Assignee: Sanofi
    Inventors: Sylviane Dumas, Georges Takerkart
  • Pharmaceutical compositions and use thereof in treating inflammation
    Patent number: 5086039
    Abstract: Inflammation in mammals is treated by administering anti-inflammatory agent complexed with corticosteroid binding globulin (CBG).
    Type: Grant
    Filed: March 4, 1991
    Date of Patent: February 4, 1992
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventor: Geoffrey L. Hammond
  • Composition of anticoagulants
    Patent number: 5084273
    Abstract: An anticoagulant containing as active ingredients protein C or activated protein C and heparin has a high anticoagulant activity which cannot be obtained with activated protein C or heparin alone. The activity of the anticoagulant is further increased by addition of AT III.
    Type: Grant
    Filed: December 21, 1990
    Date of Patent: January 28, 1992
    Assignee: Hoechst Japan Limited
    Inventor: Keizo Hirahara
  • Type II bacterial Fc receptors
    Patent number: 5082931
    Abstract: A type II, proteinaceous, antigenic factor derived from a Group A streptococci which is a receptor for the Fc region of human Ig G3 and which exhibits a major diffuse protein band on polyacrylamide gel electrophoresis and which has a molecular weight of about 38,000 daltons.
    Type: Grant
    Filed: August 21, 1989
    Date of Patent: January 21, 1992
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Michael D. P. Boyle, Michele Yarnall
  • Specific antibody-containing substance from eggs and method of production and use thereof
    Patent number: 5080895
    Abstract: A substance which contains a specific antibody or specific transfer factor-like component is produced from the yolks or albumens or both of eggs of a hen which has been immunized against a selected antigen such as a pathogenic bacteria. The substance is active against the antigen, and is useful for protecting animals from attack by the same antigen as used in immunization of the hen. It is also useful as additives in food for animals, cosmetics, and medicines. The transfer factor-like component is recovered from a fraction of at most 10,000 in molecular weight of the yolks or albumens or both of the eggs.
    Type: Grant
    Filed: April 1, 1991
    Date of Patent: January 14, 1992
    Assignee: Ghen Corporation
    Inventor: Hideo Tokoro
  • Sustained-release preparation
    Patent number: 5081156
    Abstract: A sustained-release preparation of indomethacin or interferon comprising the active ingredient in admixture with a pharmaceutically acceptable biodegradable carrier, particularly a carrier selected from collagen, gelatin, and a mixture thereof. Said preparation is particularly suitable for parenteral administration and can release the active ingredient in an effective amount for a long period of time.
    Type: Grant
    Filed: May 30, 1989
    Date of Patent: January 14, 1992
    Assignee: Sumitomo Pharmaceuticals Company, Ltd.
    Inventors: Yoshiya Yamahira, Keiji Fujioka, Shigeji Sato